Host Kenneth Cukier explores the science honoured in this year’s Nobel prizes. Our correspondents assess the life-saving impact of the identification of hepatitis C, speak to one of this year’s winners for physics, Andrea Ghez, about her work unveiling the mysteries of the cosmos, and hear from Jennifer Doudna, co-developer of CRISPR-Cas9, on the potential of genome editing. Plus, can the awards adapt to modern science?
Please subscribe to The Economist for full access to print, digital and audio editions: www.economist.com/podcastoffer Hosted on Acast. See acast.com/privacy for more information.

Babbage: Nobel minds

Every weekday our global network of correspondents makes sense of the stories beneath the headlines. We bring you surprising trends and tales from around the world, current affairs, business and finance &mdash; as well as science and technology. &nbsp; Hosted on Acast. See acast.com/privacy for more information.

News & Politics

News

Police clashes with protesters at Columbia University have spilled over into other institutions, raising the question of how to protect free speech on campuses. Given America’s history with students’ anti-war protests going awry, should politicians be worried? Why most British voters now think Brexit was a mistake (we did warn you!) (08:53) And, could new tech protect whales from speeding ships (15:45)?
Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+
For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  
 Hosted on Acast. See acast.com/privacy for more information.

The Intelligence: America’s college crackdowns

The companies behind this wonder of tech are facing allegations of using copyrighted material to build their large language models (LLMs). But will the courts consider it fair use? Why ex-inmates are so likely to die just after they leave prison (10:15). And, the case for booing in sports (16:13). 
Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+
For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.

The Intelligence: AI rest my case

At a time when Russia has been making significant gains, an allocated $61bn of aid for Ukraine will be felt on the battlefield almost instantly. Will it help turn the course of the war? In a world of endless supply chain disruptions, how can businesses shore up against the costs (11:26)? And the appeal of two-month-old stew (18:37).
Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+
For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.

The Intelligence: Ready, Aid, Fire

A missile has reportedly struck a site in the Islamic Republic. If this is retaliation for Iran’s most recent attacks, then it is a muted response. But is there still a risk of escalation? As India’s election kicks off, a look into why the opposition is likely to have a poor showing (09:07). And, a tribute to the first foreign-born grand champion of sumo (19:15).
Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+
For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

The Intelligence: Iran and Israel’s new era?

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that can help people shed up to a fifth of their body weight. But these drugs promise to do more than boost drug companies’ profits. How will they reshape the economy?
Hosts: Alice Fulwood, Mike Bird and Tom Lee-Devlin. Guests: The Economist’s Georgia Banjo; pharmaceuticals analyst Michael Nedelcovych; and John Cawley, a professor of public policy and economics at Cornell University.
Subscribers to Economist Podcasts+ can listen to our January 2023 episode on the economics of thinness.
Sign up for our new weekly newsletter dissecting the big themes in markets, business and the economy at www.economist.com/moneytalks 
Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+
For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Babbage: Nobel minds

Download our free app to listen on your phone